NCT06255210View on ClinicalTrials.gov

Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2030

Conditions
Olfactory Neuroblastoma
Interventions
DRUG

Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)

When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.

Trial Locations (1)

200031

RECRUITING

Eye & ENT Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Hongmeng Yu

OTHER